Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas
NCT ID: NCT00918853
Last Updated: 2015-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
156 participants
INTERVENTIONAL
2008-08-31
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multivisceral Oncological Resections Involving the Pancreas - An International Multicenter Study
NCT07091097
The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer
NCT04902352
Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer
NCT07232810
Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer
NCT06999512
Evaluation of the Effectiveness of Intraoperative Frozen Section on the Treatment of Suspected Gallbladder Cancer
NCT06189664
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Evaluation of the prognosis role of the invasion of the margins on the overall survival after a standard resection of adenocarcinoma of the head of the pancreas.
Secondary objectives:
* Evaluation of the prognosis role of the invasion:
* Of margins on the overall survival.
* Of each margins (distal pancreatic margin, gastric, posterior, retro-venous, retro-arterial) on the overall survival.
* Of the ganglionic group of the superior mesenteric artery and the other nodes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
resection for adenocarcinoma
quality standard resection for adenocarcinoma of the head of the pancreas
resection of adenocarcinoma of the head of the pancreas
quality standard for the resection of adenocarcinoma of the head of the pancreas
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
resection of adenocarcinoma of the head of the pancreas
quality standard for the resection of adenocarcinoma of the head of the pancreas
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* tumor apparently removable
* patient aged from 18 to older
* signed consent
* pregnancy, breast feeding
* patient in an urgency situation or patient with legal protection
Exclusion Criteria
* analysis of the margins not done with the defined criteria
* nonadhesion to the surgical protocol
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Paoli-Calmettes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Robert DELPERO, PhD
Role: PRINCIPAL_INVESTIGATOR
Institut Paoli-Calmettes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu D'Angers
Angers, , France
Chu de Bordeaux
Bordeaux, , France
Hopital Ambroise Pare
Boulogne, , France
Chu de Clermont-Ferrand
Clermont-Ferrand, , France
Hopital Beaujon
Clichy, , France
Hopital Henri Mondor
Créteil, , France
Hopital de L'Antiquaille
Lyon, , France
Hopital de La Croix-Rousse
Lyon, , France
Hospices Civils de Lyon
Lyon, , France
Chu La Conception
Marseille, , France
Institut Paoli-Calmettes
Marseille, , France
Centre Val D'Aurelle Paul Lamarque
Montpellier, , France
Hotel Dieu
Nantes, , France
Hopital Cochin
Paris, , France
Hopital Pitie-Salpetriere
Paris, , France
Hopital Tenon
Paris, , France
Hopitial Saint Antoine
Paris, , France
Hopital Pontchaillou
Rennes, , France
Hopitaux Universitaires de Strasbourg
Strasbourg, , France
Chu Purpan
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Delpero JR, Jeune F, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Adham M, Autret A, Poizat F, Turrini O, Boher JM. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. Ann Surg. 2017 Nov;266(5):787-796. doi: 10.1097/SLA.0000000000002432.
Delpero JR, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Autret A, Turrini O, Monges-Ranchin G, Boher JM. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford). 2014 Jan;16(1):20-33. doi: 10.1111/hpb.12061. Epub 2013 Mar 7.
Related Links
Access external resources that provide additional context or updates about the study.
OFFICIAL WEB SITE OF THE SPONSOR
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID-RCB 2007-A01326-47
Identifier Type: -
Identifier Source: secondary_id
MRP/IPC 2007-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.